

A Narrative Review of Clinical Decision Support for Inpatient Clinical Pharmacists

Liang Yan¹ Thomas Reese² Scott D. Nelson³

¹University of Utah College of Pharmacy, University of Utah Health, Salt Lake City, Utah, United States

²Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, Utah, United States

³Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, United States

Address for correspondence Liang Yan, PharmD, University of Utah College of Pharmacy, University of Utah Health, 30 South 2000 E, Salt Lake City, UT 84112, United States (e-mail: Liang.Yan@pharm.utah.edu).

Appl Clin Inform 2021;12:199–207.

Abstract

Objective Increasingly, pharmacists provide team-based care that impacts patient care; however, the extent of recent clinical decision support (CDS), targeted to support the evolving roles of pharmacists, is unknown. Our objective was to evaluate the literature to understand the impact of clinical pharmacists using CDS.

Methods We searched MEDLINE, EMBASE, and Cochrane Central for randomized controlled trials, nonrandomized trials, and quasi-experimental studies which evaluated CDS tools that were developed for inpatient pharmacists as a target user. The primary outcome of our analysis was the impact of CDS on patient safety, quality use of medication, and quality of care. Outcomes were scored as positive, negative, or neutral. The secondary outcome was the proportion of CDS developed for tasks other than medication order verification. Study quality was assessed using the Newcastle–Ottawa Scale.

Results Of 4,365 potentially relevant articles, 15 were included. Five studies were randomized controlled trials. All included studies were rated as good quality. Of the studies evaluating inpatient pharmacists using a CDS tool, four showed significantly improved quality use of medications, four showed significantly improved patient safety, and three showed significantly improved quality of care. Six studies (40%) supported expanded roles of clinical pharmacists.

Conclusion These results suggest that CDS can support clinical inpatient pharmacists in preventing medication errors and optimizing pharmacotherapy. Moreover, an increasing number of CDS tools have been developed for pharmacists' roles outside of order verification, whereby further supporting and establishing pharmacists as leaders in safe and effective pharmacotherapy.

Keywords

- ▶ clinical decision support
- ▶ pharmacy information systems
- ▶ inpatient care
- ▶ pharmacy
- ▶ clinical informatics
- ▶ pharmacist

Background and Significance

Pharmacists' roles have expanded from traditional medication verification and dispensing to team-based patient care.^{1,2} Since the early 1970s, pharmacists have been tangentially involved with inpatient care through pharmacokinetic consultations. More recently, pharmacists are assuming providers' roles with

collaborative practice agreements, which in some cases allow them to manage chronic health care conditions, such as diabetes and cardiovascular conditions.¹ Clinical pharmacists' roles are becoming more specialized through pharmacy residency training programs and specialty certification, and they are recognized as crucial members of the multidisciplinary health

received

August 25, 2020

accepted after revision

December 14, 2020

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG,

Rüdigerstraße 14,

70469 Stuttgart, Germany

DOI <https://doi.org/>

10.1055/s-0041-1722916.

ISSN 1869-0327.

care team.³ As with providers, clinical pharmacists can be supported by health information technology, which has been considered a major factor in preventing medication errors and patient harm.²

Electronic health record (EHR) adoption and clinical decision support (CDS) implementation have also expanded in recent years.⁴ As of 2017, 94% of U.S. hospitals used an EHR system.⁴ CDS has been characterized as a health information technology that provides patient-specific information that is intelligently filtered and presented at appropriate times for decision making.⁵⁻⁷ CDS can be developed and refined through clinician observations, suggestions, and preferences.⁸⁻¹⁰ Some examples of CDS include passively providing clinicians with helpful information without interrupting their workflow or process, such as order facilitators (e.g., order sets and default settings), relevant information displays (e.g., info-buttons and links to additional resources), and even in-line displays of information (e.g., allergy or dose alerts).¹¹ CDS also includes active or interruptive alerting, such as hard-stop alerts and reminders. Unfortunately, even with more EHRs and CDS, deaths from medication errors still occur at an alarming rate.¹²

Pharmacists play a crucial role in identifying and preventing medication errors and CDS tools can help improve pharmacists' proficiency. A study found that 64% of prescribing errors could be prevented with pharmacists and CDS. The authors concluded that pharmacists' involvement is crucial for achieving maximum medication safety.¹ Moreover, systematic reviews have examined the impact of CDS on a broad range of pharmacy services, demonstrating the benefit of combining pharmacists and CDS.^{13,14} Pharmacists not only use the EHR and CDS, but they also contribute to their design and implementation.¹⁵ By including pharmacists in CDS design and implementation, the performance and reliability can be increased.¹⁶

With pharmacists assuming more clinical roles and more CDS tools being developed to support those roles, there is a need to examine the impact of CDS on clinical pharmacy practice. In this study we present a review of the literature regarding the impact of CDS and how it has evolved with clinical pharmacists. We anticipated that inpatient pharmacists using CDS will improve outcomes and that recent CDS supports pharmacists' roles beyond medication verification and dispensing (→Fig. 1).

Methods

The study protocol was registered in PROSPERO (CRD42015016952).¹⁷ We conducted a review of published studies to evaluate the impact of the CDS tools targeted at pharmacists in the inpatient setting. We aligned this review with the PRISMA guidelines and methods from the Cochrane Handbook.¹⁸

Search Strategy and Study Eligibility

Working with a medical librarian, we identified cohort studies, observational studies, randomized control trials, and quasi-experimental studies, by searching MEDLINE, EMBASE, and Cochrane Central between January 2009 and October 2020. The search strategy was developed for MEDLINE using PubMed and iteratively refined to capture preidentified studies (→Table 1). We combined keywords, headings, and other search strategies to develop search terms. Once the search strategy was refined with PubMed, we adapted to the other databases. Study inclusion criteria are provided in →Table 2. Studies were excluded if there was no computerized system involved; the computerized system was not designed with pharmacists as the intended recipients; or the study was not in English. We used Covidence (Melbourne, Australia) to screen studies.¹⁹ Two reviewers




Fig. 1 Expanding roles of pharmacists.

Table 1 Pharmacy CDS review: PubMed search strategy

| Search terms were translated to EMBASE and Cochrane Central database |
|---|
| (“Medical Order Entry Systems/utilization”[Mesh] OR “Online Systems”[Mesh] OR “User-Computer Interface”[Mesh] OR “Medical Informatics Computing”[Mesh] OR “Medical Informatics”[Mesh] OR “Medical Informatics Applications”[Mesh] OR “Medical Order Entry Systems”[Mesh] OR “Pharmacist intervention” [All Fields] OR “Drug Prescriptions”[Mesh] OR “Electronic Prescribing”[Mesh] OR “Medication Systems”[Mesh] OR “Drug Therapy, Computer-Assisted”[Mesh] OR “Medication Errors”[Mesh] OR “Computerized p**” [All Fields] OR “Electronic p**” [All Fields] OR “CPOE”[All Fields] OR “Computerized order entry”[All Fields] OR “Electronic order entry”[All Fields] OR “Medication Reconciliation”[Mesh] OR “Pharmacists/organization and administration”[Mesh] OR “Drug Information Services”[Mesh] OR “Drug Interactions”[Mesh] OR “Guideline Adherence”[Mesh] OR “Practice Patterns, Pharmacists” [All Fields] OR “Medication review” [All Fields] OR “Medication admin*” [All Fields] OR “Clinical Pharmacy Information Systems”[Mesh] OR “Pharmacy Service, Hospital”[Mesh] OR “Pharmaceutical Services”[Mesh] OR “antimicrobial steward*” [tiab] OR “antibiotic steward*” [tiab] OR “pharmacokinetic service”[tiab] OR Pharmacotherapy [all fields]) AND (“Decision Support Systems, Clinical”[Mesh] OR “Decision Making, Computer-Assisted”[Mesh] OR “Decision support” [All Fields] OR “electronic alerts”[All Fields] OR “computer alerts”[All Fields] OR “computerized alerts”[All Fields] OR CDS*[All Fields] OR “Reminder Systems”[Mesh] OR Remind*[All Fields] OR Alert*[All Fields] OR Prompt*[All Fields] OR Notif*[All Fields] OR Interrupt*[All Fields] OR electronic display [all fields]) AND (“Pharmacists”[Mesh] OR pharmacist*[All Fields]) AND (“2009/01/01”[PDAT]: “2018/12/01”[PDAT]) |

Abbreviation: CDS, clinical decision support.

independently screened title/abstracts and full texts and a third reviewer resolved any disputes.

Quality Assessment

Since the included studies had different designs and outcomes, we used the Newcastle–Ottawa Scale to assess study quality.²⁰ Two reviewers independently assessed each included study. Additionally, it was noted whether the study conducted proper statistical analyses and whether the authors had mentioned possible contamination of the study groups.

Reporting and Analysis

Outcomes were grouped into three main categories: quality use of medication, drug and pharmacotherapy safety, and quality of care. Quality use of medication was defined as the accuracy of medication use and proper management of disease, such as appropriate dosing of medications. Drug and pharmacotherapy safety was defined as the safety of medication use, which was demonstrated by avoiding adverse events or death. Quality of care was defined as patient outcomes, which included parameters such as patient satisfaction and hospital length of stay.

The impact of the CDS intervention was characterized by assigning labels for each study result: “+” study favored the CDS intervention; “–” study favored the control group; “0” was no difference between the intervention and control groups; and “NS” the study did not conduct any statistical analysis or that there was no statistically significant data reported for the specified outcome.

We reported outcome data on whether studies demonstrated at least one positive outcome (i.e., general trend in favor of CDS for a prescribing, clinical, or patient outcome) and statistically significant improvements in favor of CDS on greater than or equal to 50% of outcomes. We chose to report trends as well as significant results given the likelihood that some studies were underpowered to detect statistically significant differences in outcomes. The outcome data are summarized in a narrative manner instead of a meta-analysis due to the heterogeneity of the study methodologies, comparison groups, intervention targets, and results.

Results

The search resulted in 4,365 articles. Based on title/abstract screening, 90 articles were selected for full-text review. Fifteen studies met the inclusion criteria (→Fig. 2). Most excluded studies were primarily focused on CDS used by providers and implementations outside the inpatient settings. Key features of the included studies are shown in →Table 3.^{20–34}


Study Quality

Of the 15 included studies, 5 were randomized controlled trials,^{27,30,31,33,34} 6 were quasi-experimental,^{22,25,28,29,32,35} 2 were observational,^{23,26} and 2 were cohort studies.^{21,24} All of the studies had a control group and all 15 studies were deemed as good quality using the Newcastle–Ottawa Scale.

Table 2 Study inclusion criteria

| | |
|---------------------------|---|
| P: participant/population | Studies listing pharmacists among recipients of the CDS system in the inpatient setting. |
| I: intervention | The described CDS system had to provide patient-specific information and/or generate information in an electronic format. |
| C: comparator/control | A comparison of performance of the CDS to routine care or other CDS or computerized prescriber order entry (CPOE) systems. |
| O: outcome | The primary outcome of the study had to include patient care, clinician effect, or processes of care. The studies also had to report measured or quantifiable outcomes, such as cost, patient outcomes, adverse drug events, clinical interventions, etc. |

Abbreviation: CDS, clinical decision support.

**Fig. 2** PRISMA diagram.

Study Characteristics

Study outcomes were analyzed in three main groups, including quality use of medication, drug and pharmacotherapy safety, and quality of care (–Table 3). Four studies examined the quality use of medications,^{23,27,31,35} seven studies looked at drug and pharmacotherapy safety,^{22,24,25,29,30,33,34} and five studies evaluated the quality of care.^{21,25,26,28,32} One study qualified as both drug and pharmacotherapy safety and quality of care. Pharmacists interacted directly with patients in one study through medication reconciliation³² and all other CDS systems did not have pharmacist–patient interactions: most of the data were based on measured laboratory results and recorded patient information by nurses and laboratory technicians.

Pharmacists were warned of potential errors through CDS alerting in 11 of the studies. For example, two studies had alerts that interrupted a pharmacist’s workflow when a patient had an abnormal serum creatinine.^{30,34} These alerts were designed to prevent medication-caused acute kidney injury and therefore required the pharmacist’s immediate attention. None of the included studies discussed alert fatigue or workflow disruption.

Other CDS interventions provided support without interrupting pharmacists’ workflow. For example, two studies examined a CDS system that calculated the dose of antibiotics for the pharmacist.^{23,35} Another study evaluated a CDS system that helped identify medication reconciliation errors.³² Finally, one study used CDS to examine cost–benefit analysis of medication use.²⁷

Table 3 Key features of the included studies

| Study | Type | Quality | Participants (n) | Intervention | Control | Outcome measures | Study results | Statistically significant |
|-----------------|---------------------------------|---------------|--|--|--|--|--|---------------------------|
| Aziz et al | Prospective cohort study | Good | 2,649 and 3,064 interventions in phase 1 (preintervention) and 2 (CDS intervention) | Electronic prompt that asks pharmacist to re-evaluate his rejected pharmacotherapy intervention | Preintervention and multidisciplinary team | Quality of care: re-evaluated a pharmacist-rejected intervention to determine it is accurate | (+) Decreased number of inappropriate rejections by 56%. | NS |
| Boussadi et al | Quasi-experimental | Good | 5,006 total alerts during the study time period. 404 decision difference between CDS alert and pharmacist | Electronic alert checks dosing error of drug orders | Pharmacist checks | Safety: dose check | (+) 50% overdoses detected by CDS while 14% detected by pharmacist. | NS |
| Claus et al | Prospective observational study | Good | 87 patients on selected antibacterial drugs that require creatinine for dose calculation | Electronic antimicrobial dose alert provides dosing advice based on 24-hour creatinine clearance | Pharmacist review | QJM: "antimicrobial dose based on SCr" (ADC) accuracy alert and pharmacist workload | (+) 78.5% correct dosing prescription. 13.4% overdosed, and 8.1% underdosed. Pharmacist time per patient reduced by 76.5%. | NS |
| Cornu et al | Prospective cohort study | Good | 50 patients followed by clinical pharmacists | CDS DDI alert system | Pharmacist check | Safety: compare rate of DDI and rate of acceptance between CDS DDI alert and pharmacist verifications | (-) 240: 6 DDIs by pharmacist; CDS (-) 81%: 0 accepted advise by physician | Statistically significant |
| Cox et al | RCT | Good | Patient started on tobramycin or amikacin during study period (97 amikacin patients and 119 tobramycin patients) | CDS dosing selection for patient initiating on tobramycin or amikacin | Preintervention | QJM: pharmacist calculated amikacin/tobramycin dose alert (within ± 10% of the study reference standard) | (+) 40% dosing accuracy in the pre-CDS arm to 80% in the post-CDS arm | Statistically significant |
| Diaz et al | Quasi-experimental | Good | 171 patients > 18 years of age admitted to medical and surgical services with an eGFR < 60 ml/min | CDS with drug-allergy checking, formulary decision support, and DDI checking | Preintervention | Safety, quality of care: evaluate the efficacy of CDS on the frequency of appropriate prescriptions. | (+) 65% pre-CDS, 86% after intervention. Correct prescription based on renal function | Statistically significant |
| Eppenga et al | Prospective observational study | Good | Patient admitted in 5 randomly chosen consecutive days. 150 alerts generated by basic CDS and 384 alerts generated by advanced CDS | Advanced medication alert CDS with multiple functionality | Basic medication alert CDS | Quality of care: compare the performance of two medication alert CDSs | (+) Advanced CDS has higher positive predicted value (17%) compared with basic CDS (5.8%). | Statistically significant |
| Study | Type | Study quality | Participants (n) | Intervention (types of CDSs) | Control | Outcome measures | Study results | Statistically significant |
| Gallagher et al | RCT and cost-effective analysis | Good | 361 patients admitted to the hospital within the study timeline were randomized into each group | CDS integrated with STOPP/START criteria for elderly patients | Preintervention | QJM: cost-effectiveness analysis of SPRM/CSSS for elderly patients | (+) CDS group was associated with a decrease of €807 in mean health care cost (+) Decrease in the mean number of ADR events per patient | NS |
| Lightfoot et al | Quasi-experimental | Good | 28 delirium patients included in the preintervention arm and 33 patients at the intervention arm. | Real-time CDS alert that notifies pharmacist of delirium patient that meet recommendation criteria | Preintervention | Quality of care: compare the delirium incidence, length of stay, and ventilator duration between CDS and control group | (+) CDS group had a nonsignificant trend in decreased incidence of delirium, ICU length of stay, and ventilator duration. (+) CDS group had a significantly shorter hospital LOS. | Statistically significant |

(Continued)

Table 3 (Continued)

| | | | | | | | | |
|--------------------------|--------------------|------|---|--|--|--|--|---------------------------|
| Mansour et al | Quasi-experimental | Good | Any admitted patient who can potentially develop hyperkalemia. | High K level alert CDS that notifies pharmacists when a drug order will further increase K level | Preintervention | Safety: effect of a hyperkalemia ADE alert | (+) 48:14 pre-CDS; post-CDS patients had hyperkalemia that required treatment. | Statistically significant |
| McCoy et al | RCT | Good | 396 patients with an acute 0.5 mg/dL change in serum creatinine over 48 hours and a nephrotoxicity or renally cleared medication order. | Web-based dynamic surveillance CDS monitors AKI by clinical pharmacists | Preintervention (patient with no surveillance tool) | Safety: AKI-related ADEs and potential ADEs within the CDS group compared with control group | (0) No statistical difference was observed between intervention and controlled group | NS |
| García-Molina Sáez et al | Quasi-experimental | Good | 321 patients admitted in the cardiopneumology unit during the study period | "Medication history documentation" CDS integrated with electronic clinical history | Preintervention | Quality of care: CDS intends to decrease medication reconciliation error | (+) The mean number of reconciliation errors per patient: preintervention, 4.4 ± 3.2 ; during intervention, 1.8 ± 2.6 ; postintervention, 3.9 ± 3.7 | Statistically significant |
| O'Sullivan et al | RCT | Good | 1,833 patients aged >65 years admitted to specialist services | CDS with structured pharmacist review of medication (SPRM) to prevent ADR | Preintervention (standard pharmaceutical care without CDS) | Safety: ADR risk reduction between CDS and control group | (+) Provider implemented 54.8% of SPRM/CDSS prescribing recommendations. Ninety-one ADRs occurred in 78 control patients (20.7%) compared with 61 ADRs in 50 CDS group patients (13.9%), an absolute risk reduction of 6.8%. | Statistically significant |
| Wilson et al | RCT | Good | 2,393 patients ≥ 18 years old with stage 1 or greater acute kidney injury | Current SCR-based AKI alert CDS sends notification to providers | Preintervention | Safety: ranking of clinical outcomes, maximum relative change in creatinine, dialysis, and death, within 7 days of randomization | (0) There was no difference between the two groups comparing the creatinine, dialysis, and death at 7 days. | Statistically significant |
| Kan et al | Quasi-experimental | Good | 332 patients receiving IV antibiotics during the entire study period | CDS converting IV antibiotics to PO dose per pharmacist | Preintervention | QUM: assessing antibiotic IV-PO conversion rate before and after CDS implementation | (+) IV-PO conversion rate was 29% (preintervention), 35% (1 month postintervention), 71% (3 months post), and 74% (15 months post) | Statistically significant |

Abbreviations: ADE, adverse drug event; ADR, adverse drug reaction; AKI, acute kidney injury; CDS, clinical decision support; CDSS, clinical decision support system; DDI, drug-drug interaction; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; IV, intravenous; LOS, length of stay; PO, per oral; RCT, randomized controlled trial; SCR, serum creatinine.

Note: "+" meaning that the study favored the CDS intervention. "-" meaning that the study favored the control group. "0" meaning that there was no difference between the intervention and the control groups. "NS" meaning that the study did not conduct any statistical analysis or that there was no statistically significant data reported for the specified result. "QUM" meaning quality use of medication.

CDS Intervention Analysis

Eight studies significantly favored the CDS intervention^{25,26,28,29,31–33,35}; 20% of the studies presented results that favored the CDS intervention without statistical significance^{21,23,27}; 13% of the studies favored the control groups^{22,24}; and 13% of the studies showed that the CDS interventions had no difference compared with the control group.^{30,34} One study²⁴ favors pharmacists' check over CDS; however, this was explained by the authors that the CDS was self-developed and lacks a high level of specificity for drug–drug interactions (DDIs).

CDS interventions covered a wide range pharmacists' practice, including dynamic monitoring, drug safety in low kidney function patients, medication safety in patients with QT prolongation, dosing calculation, medication reconciliation, and general medication use and safety. Eleven of the 14 studies examined CDS application outside medication verification.^{21,23,27–35} Among the 11 studies, 82% presented results that favored the CDS intervention with statistical significance,^{21,23,27–29,31–33,35} 18% of the studies showed that the CDS interventions had no difference compared with the control group,^{30,34} and no study favored the control group.

Discussion

This study demonstrated that CDS interventions developed for clinical pharmacists can improve health care outcomes. Notably, all studies that evaluated quality use of medication and quality of care showed improved outcomes. Moreover, CDS seems to be evolving with clinical pharmacists' roles, since the majority of studies evaluated an intervention outside order verification tasks.

When compared with CDSs in other settings, studies conducted in community pharmacy practice examined workflow consequences, interactions with patients more frequently, and relied less on EHR information, such as laboratory results.^{15,36} Previous studies have examined CDS that supports prescribing in community and hospital pharmacy settings.^{13,36} These studies concluded that workflow disruption and alert fatigue were major issues causing pharmacists to ignore CDS alerts and prompts. In the present review, we did not identify or conclude that workflow or alert fatigue was a problem. The lack of alert fatigue discussion in the included studies may be the result of the inpatient setting where patient data can be used to refine alert triggers, making alerts more specific. However, we do believe that alert fatigue is still an issue for pharmacists in the inpatient setting given the amount of CDS.³⁷

One of the aims of this review was to examine how CDS is meeting the need of clinical pharmacists providing patient care. We found the majority of CDS interventions still focus on drug dosing, DDIs, and identifying or preventing adverse effects; however, we did find CDS interventions that have expanded to other clinical areas, such as managing acute kidney injury, and managing cardiovascular diseases. Also, CDS interventions supported specialized services in the emergency department, geriatric wards, trauma units, and

other units.^{9–11,15–19,21,22} These findings suggest that CDS is supporting specialized and decentralized pharmacists' roles in a variety of clinical domains in hospital departments.

Concerns remain on whether advanced CDS systems will replace pharmacists and reduce the number of pharmacy jobs. Based on the included studies, this does not seem to be the case as the majority of CDS interventions were basic alerts and prompts. Two studies used CDS to calculate antimicrobial dosing, but the ultimate decision was still based on pharmacists' discretion. There were no signs that implementation of CDS could replace clinical pharmacists, rather it is more likely that CDS is helping pharmacists increase their efficiency and patient safety.³⁸

Limitations of this study should be noted. First, we were unable to conduct meta-analysis due to the heterogeneity of included studies. Second, we only queried studies published in three databases, which means there could be other published (or unpublished) studies that were not included. Finally, the majority of the studies showed a benefit from using CDS, which suggests publication bias may be present.

Conclusion

With more than 73% of studies examining CDS outside medication verifications and 82% of studies favoring the intervention, these findings suggest CDS implementations targeted toward clinical pharmacists have been increasing and improving as pharmacists' roles are becoming more clinical and patient-orientated. We anticipate that as the clinical pharmacy's role expands into more specialized health care fields, CDS interventions will also expand to support pharmacists and improve patient care.

Clinical Relevance Statement

This review showed that between 2009 and 2020, multiple studies examined clinical pharmacist related nonverification CDS and showed positive results that the CDS facilitates pharmacist's workflow in clinical settings. These CDSs were developed to accommodate the expanding roles of pharmacists. This review has indicated continuous progress for pharmacists to contribute in clinical patient care and makes pharmacist an important member in medical interdisciplinary team.

Multiple Choice Questions

- Which of the following pharmacists' roles can be best facilitated by inpatient CDS systems (up to 2)?
 - Pharmacists supervise the medicine supply chain.
 - Pharmacists counsel patients on safe and effective medicine use.
 - Pharmacists advise other health care professionals about safe and effective medicine use.
 - Pharmacists monitor patient's health conditions and determine safety and efficacy of their current medication.

Correct Answer: The correct answers are options a and d. CDS systems can be implemented to monitor patient's health conditions or decrease medicine cost. CDS cannot replace pharmacists to counsel patients or advise health care professionals.

2. Which of the following is not a keyword used to determine included studies of this review?
- Pharmacist
 - Computerized
 - Clinical
 - Doctor

Correct Answer: The correct answer is option d. This study reviews CDSs used by pharmacists in inpatient/clinical settings. Doctors are not part of the inclusion criteria.

Protection of Human and Animal Subjects

There were no human subjects involved in this project.

Conflict of Interest

None declared.

Acknowledgment

This study was supported by University of Utah College of Pharmacy. Also, we are very thankful to the editorial board of Applied Clinical Informatics journal for their valuable and constructive comments.

References

- Dolovich L, Austin Z, Waite N, et al. Pharmacy in the 21st century: enhancing the impact of the profession of pharmacy on people's lives in the context of health care trends, evidence and policies. *Can Pharm J* 2018;152(01):45–53
- Francis J, Abraham S. Clinical pharmacists: bridging the gap between patients and physicians. *Saudi Pharm J* 2014;22(06):600–602
- Carter BL. Evolution of clinical pharmacy in the USA and future directions for patient care. *Drugs Aging* 2016;33(03):169–177
- Saiyed SM, Davis KRKD, Kaelber DC. Differences, opportunities, and strategies in drug alert optimization-experiences of two different integrated health care systems. *Appl Clin Inform* 2019;10(05):777–782
- Health IT. Clinical decision support. The Office of the National Coordinator for Health Information Technology. Accessed January 8, 2021 at: https://www.healthit.gov/sites/default/files/page/2018-04/Optimizing_Strategies_508.pdf
- Lainer M, Mann E, Sönnichsen A. Information technology interventions to improve medication safety in primary care: a systematic review. *Int J Qual Health Care* 2013;25(05):590–598
- Ibáñez-García S, Rodríguez-González C, Escudero-Vilaplana V, et al. Development and evaluation of a clinical decision support system to improve medication safety. *Appl Clin Inform* 2019;10(03):513–520
- Ozkaynak M, Metcalf N, Cohen DM, May LS, Dayan PSMR, Mistry RD. Considerations for designing EHR-embedded clinical decision support systems for antimicrobial stewardship in pediatric emergency departments. *Appl Clin Inform* 2020;11(04):589–597
- Wang J, Liang H, Kang H, Gong Y. Understanding health information technology induced medication safety events by two conceptual frameworks. *Appl Clin Inform* 2019;10(01):158–167
- Unberath P, Prokosch HU, Gründner J, Erpenbeck M, Maier C, Christoph J. EHR-independent predictive decision support architecture based on OMOP. *Appl Clin Inform* 2020;11(03):399–404
- Wright A, Sittig DF, Ash JS, et al. Development and evaluation of a comprehensive clinical decision support taxonomy: comparison of front-end tools in commercial and internally developed electronic health record systems. *J Am Med Inform Assoc* 2011;18(03):232–242
- Lyell D, Magrabi F, Coiera E. Reduced verification of medication alerts increases prescribing errors. *Appl Clin Inform* 2019;10(01):66–76
- Curtain C, Peterson GM. Review of computerized clinical decision support in community pharmacy. *J Clin Pharm Ther* 2014;39(04):343–348
- Zeng X, Zhang Y, Kwong JSW, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. *J Evid Based Med* 2015;8(01):2–10
- Nelson SD, Poikonen J, Reese T, El Halta D, Weir C. The pharmacist and the EHR. *J Am Med Inform Assoc* 2017;24(01):193–197
- Saverno KR, Hines LE, Warholak TL, et al. Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. *J Am Med Inform Assoc* 2011;18(01):32–37
- Nelson S, Newbold J, Reese T, et al. Computerized clinical decision support systems for clinical pharmacy in the MeaningfulUse Era: a systematic review. National Institute for Health Research. Published January 8, 2021 at: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=16952
- Chandler J, Higgins JPT, Deeks JJ, Davenport C, Clarke MJ. Chapter 1: Introduction. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, eds. *Cochrane Handbook for Systemic Reviews of Interventions* version 5.2.0. 2017:1–11
- Covidence. Accessed January 8, 2021 at: <https://www.covidence.org/>
- Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Ottawa Hospital Research Institute. Published 2019. Accessed January 8, 2021 at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
- Aziz MT, Rehman TU, Qureshi S, Andleeb S. Effects of multidisciplinary teams and an integrated follow-up electronic system on clinical pharmacist interventions in a cancer hospital. *Int J Clin Pharm* 2017;39(06):1175–1184
- Boussadi A, Caruba T, Karras A, et al. Validity of a clinical decision rule-based alert system for drug dose adjustment in patients with renal failure intended to improve pharmacists' analysis of medication orders in hospitals. *Int J Med Inform* 2013;82(10):964–972
- Claus BOM, Colpaert K, Steurbaut K, et al. Role of an electronic antimicrobial alert system in intensive care in dosing errors and pharmacist workload. *Int J Clin Pharm* 2015;37(02):387–394
- Cornu P, Steurbaut S, Soštarić S, Mrhar A, Dupont AG. Performance of a clinical decision support system and of clinical pharmacists in preventing drug-drug interactions on a geriatric ward. *Int J Clin Pharm* 2014;36(03):519–525
- Díaz A, Saez de la Fuente J, Esteva L, et al. Drug prescribing in patients with renal impairment optimized by a computer-based, semi-automated system. *Int J Clin Pharm* 2013;35(06):1170–1177
- Eppenga WL, Derijks HJ, Conemans JMH, Hermens WAJJ, Wensing M, De Smet PAGM. Comparison of a basic and an advanced pharmacotherapy-related clinical decision support system in a hospital care setting in the Netherlands. *J Am Med Inform Assoc* 2012;19(01):66–71
- Gallagher J, O'Sullivan D, McCarthy S, et al. Structured pharmacist review of medication in older hospitalised patients: a cost-effectiveness analysis. *Drugs Aging* 2016;33(04):285–294

- 28 Lightfoot M, Sanders A, Burke C, Patton J. Clinical pharmacist impact on intensive care unit delirium: intervention and monitoring. *Hosp Pharm* 2019;54(03):180–185
- 29 Mansour H, Dilkhush D, Lannigan J, Whalen KL. The impact of a computerized potassium alert on adverse drug events and pharmacists' interventions. *J Pharm Technol* 2010;26(02):55–59
- 30 McCoy AB, Cox ZL, Neal EB, et al. Real-time pharmacy surveillance and clinical decision support to reduce adverse drug events in acute kidney injury: a randomized, controlled trial. *Appl Clin Inform* 2012;3(02):221–238
- 31 Cox Z, Nelsen C, Waitman L, McCoy J, Peterson J. Clinical decision support improves initial dosing and monitoring of tobramycin and amikacin. *Am J Health Syst Pharm*. 2008;23(01):1–7
- 32 García-Molina Sáez C, Urbieto Sanz E, Madrigal de Torres M, Vicente Vera T, Pérez Cárceles MD. Computerized pharmaceutical intervention to reduce reconciliation errors at hospital discharge in Spain: an interrupted time-series study. *J Clin Pharm Ther* 2016;41(02):203–208
- 33 O'Sullivan D, O'Mahony D, O'Connor MN, et al. Prevention of adverse drug reactions in hospitalised older patients using a software-supported structured pharmacist intervention: a cluster randomised controlled trial. *Drugs Aging* 2016;33(01):63–73
- 34 Wilson FP, Shashaty M, Testani J, et al. Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial. *Lancet* 2015;385(9981):1966–1974
- 35 Kan T, Kwan D, Chan T, Das P, Raybardhan S. Implementation of a clinical decision support tool to improve antibiotic IV-to-oral conversion rates at a community academic hospital. *Can J Hosp Pharm* 2019;72(06):455–461
- 36 Robertson J, Walkom E, Pearson SA, Hains I, Williamsone M, Newby D. The impact of pharmacy computerised clinical decision support on prescribing, clinical and patient outcomes: a systematic review of the literature. *Int J Pharm Pract* 2010;18(02):69–87
- 37 Reese TJ, Kawamoto K, Del Fiore G, et al. When an alert is not an alert: a pilot study to characterize behavior and cognition associated with medication alerts. *AMIA Annu Symp Proc* 2018: 1488–1497
- 38 Friedman CPA. A “fundamental theorem” of biomedical informatics. *J Am Med Inform Assoc* 2009;16(02):169–170